3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Compound heterozygous loss of function variants in MYL9 in a child with megacystis–microcolon–intestinal hypoperistalsis syndrome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Megacystis–microcolon–intestinal hypoperistalsis syndrome (MMIHS), or “visceral myopathy,” is a severe early onset disorder characterized by impaired muscle contractility in the bladder and intestines. Five genes are linked to MMIHS: primarily ACTG2, but also LMOD1, MYH11, MYLK, and MYL9. Here we describe a three‐year‐old girl with bilateral hydronephrosis diagnosed at 20 weeks gestation and congenital mydriasis (both of which have been previously observed among individuals with MMIHS). A clinical diagnosis of MMIHS was made based upon the presence of megacystis, lack of urinary bladder peristalsis, and intestinal pseudo‐obstruction. After initial testing of ACTG2 was negative, further sequencing and deletion/duplication testing was performed on the LMOD1, MYH11, MYLK, and MYL9 genes. We identified two heterozygous loss of function variants in MYL9: an exon 4 deletion and a nine base pair deletion that removes the canonical splicing donor site at exon 2 (NM_006097.5:c.184+2_184+10del). Parental testing confirmed these variants to be in trans in our proband. To our knowledge, only one other individual with MMIHS has biallelic mutations in MYL9 (a homozygous deletion encompassing exon 4). We suggest MYL9 be targeted on genetic testing panels for MMIHS, smooth muscle myopathies, and cardiovascular phenotypes.

          Abstract

          In this manuscript, we describe a proband with a clinical diagnosis of congenital MMIHS and two rare compound heterozygous loss of function variants in MYL9, which we confirmed to be in trans by parental testing. To our knowledge, this is only the second peer‐reviewed report of a genetically characterized case of MYL9‐associated MMIHS and supports the gene‐disease association between MYL9 and MMIHS with an autosomal recessive inheritance pattern. We conclude that MYL9 be targeted on genetic testing panels for MMIHS, smooth muscle myopathies, and cardiovascular phenotypes.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

          The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants. 1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next generation sequencing. By adopting and leveraging next generation sequencing, clinical laboratories are now performing an ever increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes and epigenetic assays for genetic disorders. By virtue of increased complexity, this paradigm shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context, the ACMG convened a workgroup in 2013 comprised of representatives from the ACMG, the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP and CAP stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories including genotyping, single genes, panels, exomes and genomes. This report recommends the use of specific standard terminology: ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’ to describe variants identified in Mendelian disorders. Moreover, this recommendation describes a process for classification of variants into these five categories based on criteria using typical types of variant evidence (e.g. population data, computational data, functional data, segregation data, etc.). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a CLIA-approved laboratory with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or equivalent.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regulation of gastrointestinal motility--insights from smooth muscle biology.

            Gastrointestinal motility results from coordinated contractions of the tunica muscularis, the muscular layers of the alimentary canal. Throughout most of the gastrointestinal tract, smooth muscles are organized into two layers of circularly or longitudinally oriented muscle bundles. Smooth muscle cells form electrical and mechanical junctions between cells that facilitate coordination of contractions. Excitation-contraction coupling occurs by Ca(2+) entry via ion channels in the plasma membrane, leading to a rise in intracellular Ca(2+). Ca(2+) binding to calmodulin activates myosin light chain kinase; subsequent phosphorylation of myosin initiates cross-bridge cycling. Myosin phosphatase dephosphorylates myosin to relax muscles, and a process known as Ca(2+) sensitization regulates the activity of the phosphatase. Gastrointestinal smooth muscles are 'autonomous' and generate spontaneous electrical activity (slow waves) that does not depend upon input from nerves. Intrinsic pacemaker activity comes from interstitial cells of Cajal, which are electrically coupled to smooth muscle cells. Patterns of contractile activity in gastrointestinal muscles are determined by inputs from enteric motor neurons that innervate smooth muscle cells and interstitial cells. Here we provide an overview of the cells and mechanisms that generate smooth muscle contractile behaviour and gastrointestinal motility.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Myocardin-Related Transcription Factors and SRF are required for cytoskeletal dynamics, invasion and experimental metastasis

              Rho GTPases control cytoskeletal dynamics through cytoplasmic effectors, and regulate transcriptional activation by the Myocardin Related Transcription Factors (MRTFs), coactivators for Serum Response Factor (SRF). We used RNAi to investigate the contribution of the MRTF-SRF pathway to cytoskeletal dynamics in MDA-MB-231 breast carcinoma and B16F2 melanoma cells, where basal MRTF-SRF activity is Rho-dependent. Depletion of MRTFs or SRF reduces cell adhesion, spreading, invasion and motility in culture, without affecting proliferation or inducing apoptosis; MRTF-depleted tumor cell xenografts exhibit reduced cell motility but proliferate normally. MRTF- and SRF-depleted tumor cells fail to colonise the lung from the bloodstream, being unable to persist following their initial arrival at the lung. Only a few genes exhibit MRTF-dependent expression in both cell lines. Two of these, MYH9 (MLC2) and MYL9 (NMHCIIa), are also required for invasion and lung colonisation. Conversely, expression of an activated MRTF increases lung colonisation by poorly metastatic B16F0 cells. Actin-based cell behaviour and experimental metastasis thus requires Rho-dependent nuclear signalling through the MRTF-SRF network.
                Bookmark

                Author and article information

                Contributors
                yxue@fulgentgenetics.com
                Journal
                Mol Genet Genomic Med
                Mol Genet Genomic Med
                10.1002/(ISSN)2324-9269
                MGG3
                Molecular Genetics & Genomic Medicine
                John Wiley and Sons Inc. (Hoboken )
                2324-9269
                08 October 2020
                November 2020
                : 8
                : 11 ( doiID: 10.1002/mgg3.v8.11 )
                : e1516
                Affiliations
                [ 1 ] Fulgent Genetics Atlanta Georgia USA
                [ 2 ] Division of Medical Genetics Department of Pediatrics Children's Hospital of Pittsburgh Pittsburgh Pennsylvania USA
                Author notes
                [*] [* ] Correspondence

                Yuan Xue, Fulgent Genetics, Atlanta, GA, USA.

                Email: yxue@ 123456fulgentgenetics.com

                Author information
                https://orcid.org/0000-0002-3493-0818
                Article
                MGG31516
                10.1002/mgg3.1516
                7667357
                33031641
                8157c959-315e-469f-a433-7ec458656e77
                © 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 25 June 2020
                : 10 September 2020
                Page count
                Figures: 1, Tables: 1, Pages: 7, Words: 4248
                Categories
                Clinical Report
                Clinical Reports
                Custom metadata
                2.0
                November 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.4 mode:remove_FC converted:16.11.2020

                congenital,loss‐of‐function,mmihs,myl9,myopathy
                congenital, loss‐of‐function, mmihs, myl9, myopathy

                Comments

                Comment on this article